german
federal
joint
committee
issues
nationwide
reimbursement
decision
breast
cancer
prognostic
test
distribution
news
wire
services
dissemination
united
states
salt
lake
city
globe
newswire
myriad
genetics
nasdaq
mygn
global
leader
molecular
diagnostics
precision
medicine
announced
today
german
federal
joint
committee
successfully
completed
method
evaluation
assessment
breast
cancer
prognostic
test
positive
decision
means
endopredict
made
available
patients
statutory
health
insurance
germany
benefit
statutory
health
insurance
scheme
endopredict
biomarker
test
used
determine
risk
recurrence
patients
breast
cancer
genomic
test
helps
patients
physicians
jointly
decide
chemotherapy
uncertainties
exist
assessment
expected
benefit
chemotherapy
decision
makes
possible
biomarker
test
carried
quickly
germany
providing
certainty
difficult
decisions
relating
pros
cons
chemotherapy
says
univ
marion
kiechle
director
gynaecological
clinic
university
hospital
rechts
der
isar
tu
munich
every
year
approximately
women
germany
diagnosed
breast
cancer
patients
criteria
alone
sufficient
confidently
make
chemotherapy
treatment
decisions
federal
joint
committee
supports
use
biomarkers
including
endopredict
identify
patients
likely
benefit
chemotherapy
treatment
endopredict
part
recommendations
leading
national
ago
international
esmo
asco
nccn
guidelines
many
years
already
available
affected
women
public
health
systems
france
england
italy
spain
switzerland
austria
pleased
make
endopredict
broadly
available
gynecologists
pathologists
germany
within
framework
gkv
said
raymond
francot
executive
vice
president
myriad
international
decision
expands
access
critical
insights
patients
providers
adds
valuable
information
aid
personalized
treatment
endopredict
molecular
prognostic
test
patients
diagnosed
breast
cancer
test
provides
vital
information
helps
clinicians
devise
personalized
treatment
plans
patients
endopredict
validated
patients
cancer
used
clinically
patients
contrast
multigene
prognostic
tests
endopredict
detects
likelihood
late
metastases
metastasis
formation
five
years
therefore
guide
treatment
decisions
regarding
need
chemotherapy
well
extended
therapy
accordingly
therapy
decisions
backed
endopredict
confer
high
level
diagnostic
safety
information
please
visit
https
endopredict
myriad
myriad
genetics
leading
precision
medicine
company
dedicated
trusted
advisor
transforming
patient
lives
worldwide
pioneering
molecular
diagnostics
myriad
discovers
commercializes
molecular
diagnostic
tests
determine
risk
developing
disease
accurately
diagnose
disease
assess
risk
disease
progression
guide
treatment
decisions
across
six
major
medical
specialties
molecular
diagnostics
significantly
improve
patient
care
lower
healthcare
costs
myriad
focused
three
strategic
imperatives
transitioning
expanding
hereditary
cancer
testing
markets
diversifying
product
portfolio
introduction
new
products
increasing
revenue
contribution
international
markets
information
myriad
making
difference
please
visit
company
website
myriad
myriad
logo
bart
bracanalysis
colaris
colaris
ap
mypath
myrisk
myriad
myrisk
myrisk
hereditary
cancer
mychoice
myplan
bracanalysis
cdx
tumor
bracanalysis
cdx
mychoice
cdx
vectra
prequel
foresight
genesight
riskscore
prolaris
trademarks
registered
trademarks
myriad
genetics
wholly
owned
subsidiaries
united
states
foreign
countries
safe
harbor
statement
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
including
statements
related
endopredict
available
patients
statutory
health
insurance
germany
without
restrictions
endopredict
broadly
available
gynecologists
pathologists
germany
decision
expanding
access
critical
insights
patients
providers
company
strategic
directives
caption
myriad
genetics
statements
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
uncertainties
associated
including
possible
effects
operations
demand
products
services
ability
efficiently
flexibly
manage
business
amid
uncertainties
related
risk
sales
profit
margins
molecular
diagnostic
tests
pharmaceutical
clinical
services
may
decline
risks
related
ability
transition
existing
product
portfolio
new
tests
including
unexpected
costs
delays
risks
related
decisions
changes
governmental
private
insurers
reimbursement
levels
tests
ability
obtain
reimbursement
new
tests
comparable
levels
existing
tests
risks
related
increased
competition
development
new
competing
tests
services
risk
may
unable
develop
achieve
commercial
success
additional
molecular
diagnostic
tests
pharmaceutical
clinical
services
timely
manner
risk
may
successfully
develop
new
markets
molecular
diagnostic
tests
pharmaceutical
clinical
services
including
ability
successfully
generate
revenue
outside
united
states
risk
licenses
technology
underlying
molecular
diagnostic
tests
pharmaceutical
clinical
services
future
tests
services
terminated
maintained
satisfactory
terms
risks
related
delays
problems
operating
laboratory
testing
facilities
healthcare
clinic
risks
related
public
concern
genetic
testing
general
tests
particular
risks
related
regulatory
requirements
enforcement
united
states
foreign
countries
changes
structure
healthcare
system
healthcare
payment
systems
risks
related
ability
obtain
new
corporate
collaborations
licenses
acquire
new
technologies
businesses
satisfactory
terms
risks
related
ability
successfully
integrate
derive
benefits
technologies
businesses
license
acquire
risks
related
projections
business
results
operations
financial
condition
risks
related
potential
market
opportunity
products
services
risk
licensors
may
unable
protect
third
parties
infringe
proprietary
technologies
underlying
tests
risk
claims
challenges
validity
patents
intellectual
property
risks
related
changes
intellectual
property
laws
covering
molecular
diagnostic
tests
pharmaceutical
clinical
services
patents
enforcement
united
states
foreign
countries
supreme
court
decisions
mayo
collab
servs
prometheus
ass
n
molecular
pathology
myriad
genetics
alice
cls
bank
int
l
risks
new
changing
competitive
technologies
regulations
united
states
internationally
risk
may
unable
comply
financial
operating
covenants
credit
lending
agreements
risk
unable
pay
due
amounts
due
credit
lending
agreements
factors
discussed
heading
risk
factors
contained
item
recent
annual
report
form
fiscal
year
ended
june
filed
securities
exchange
commission
well
updates
risk
factors
filed
time
time
quarterly
reports
form
current
reports
form
information
press
release
date
release
myriad
undertakes
duty
update
information
unless
required
law
